Antibiotic resistance - Prevention and Stewardship Strategies

Prevention and Control Strategies for Antimicrobial Resistance Introduction As antimicrobial resistance (AMR) continues to spread globally, a comprehensive approach is needed to slow its development and limit its impact. The good news is that resistance is not inevitable—it can be prevented and controlled through deliberate strategies. Rather than waiting for new drugs to solve the problem, the most effective current approaches focus on antimicrobial stewardship: using antimicrobials more wisely, preventing infections from occurring in the first place, and coordinating efforts across human health, animal health, and environmental sectors. Understanding Antimicrobial Stewardship Antimicrobial stewardship refers to the coordinated efforts to select the right antimicrobial, at the right dose, for the right duration, to treat the right patient. Think of it as preventing the unnecessary "training" of bacteria to resist our drugs. The diagram above illustrates a fundamental principle: when non-resistant bacteria are exposed to antibiotics, they die. But resistant bacteria survive and multiply, spreading to others. Stewardship aims to reduce these opportunities for resistant bacteria to flourish by eliminating unnecessary antibiotic use. Hospital-Level Stewardship Programs In hospitals, specialized antimicrobial stewardship teams consist of pharmacists, infectious disease specialists, and other clinical staff who monitor antibiotic prescribing and provide feedback to clinicians. These teams work by: Reviewing prescriptions before or shortly after antibiotics are started to ensure they're truly necessary and appropriately chosen Providing education to clinicians about current resistance patterns and evidence-based prescribing Setting protocols that guide treatment decisions for common infections Research shows these interventions have real, measurable benefits. Hospital stewardship programs can shorten patient stays by approximately one day without increasing mortality rates—meaning patients leave sooner, are exposed to less institutional bacteria, and benefit from more targeted therapy. The image above shows practical recommendations that stewardship teams promote: ordering cultures before starting antibiotics when possible, specifying dose and duration clearly, and reassessing therapy within 48 hours to stop unnecessary antibiotics early. Primary-Care and Individual-Level Strategies Hospitals aren't the only setting where stewardship matters. The majority of antibiotics are prescribed in primary care—offices, clinics, and emergency departments—where many infections don't actually require antibiotics. Decision Support and Education Primary-care stewardship uses several proven approaches: Written patient information explaining when antibiotics don't work has been shown to reduce antibiotic prescribing for common upper-respiratory infections. Many patients request antibiotics expecting them to work against viruses, when in fact viruses are the actual cause. Decision-support tools help clinicians systematically determine whether an antibiotic is truly needed. These might be simple questions: "Does this patient have signs of a bacterial infection?" or "Has the patient had symptoms long enough that bacterial involvement is likely?" Adequate consultation time and plain-language explanations for parents are particularly important in pediatric settings. When parents understand that their child's cold is viral and will resolve on its own, they're less likely to request antibiotics—and less likely to give leftover antibiotics to another family member later. The "Five Rights" of Drug Administration A practical framework that guides primary-care prescribers is the "five rights" of drug administration: Right patient — Confirming the prescription is for the correct person Right drug — Selecting an appropriate antimicrobial based on the likely infection Right dose — Prescribing the correct amount for the patient's age and weight Right route — Using the appropriate administration route (oral, intravenous, etc.) Right time — Starting at the right moment in the infection course These five rights seem straightforward, but they're often overlooked in busy clinical settings. Individual Patient Responsibilities Patients themselves play a crucial role in stewardship: Take antibiotics only when prescribed by a qualified health professional for a bacterial infection. Don't self-treat or use antibiotics from previous illnesses. Complete the full prescribed course, even if symptoms improve. Stopping early can leave behind surviving bacteria that then develop resistance. Never share antibiotics with others, and don't use leftover medication. This practice provides no benefit to the recipient and selects for resistant bacteria. Practice basic infection prevention: regular hand hygiene, not sharing drinks or eating utensils, and staying home when sick prevent the spread of resistant organisms. The WHO AWaRe Classification System To guide more targeted prescribing, the World Health Organization developed the AWaRe classification, which categorizes antibiotics into three groups: Access antibiotics are narrow-spectrum, effective for common infections, and should be the first choice whenever possible. These are typically older, well-understood drugs like penicillins and cephalosporins for most bacterial infections. Using these preserves newer drugs for more serious infections. Watch antibiotics have a higher resistance potential and should be reserved for specific infections when Access options have failed or are inappropriate. These are used more cautiously and with closer monitoring. Reserve antibiotics are the last line of defense for serious multidrug-resistant infections and should rarely be used. Keeping these in reserve maximizes their future usefulness. By promoting the use of Access antibiotics first, the AWaRe system reduces the selective pressure on bacteria to develop resistance to the more powerful drugs we might need later. It's a strategy of "preservation through restraint." Limiting Antimicrobial Use in Animals Historically, antibiotics were used extensively in animal agriculture—not just to treat disease, but to promote growth in healthy animals. This practice created massive selective pressure for resistance in agricultural bacteria, which could then spread to human populations through the food chain. Many countries have enacted restrictions on growth-promotion antibiotics in animals. The results have been measurable: countries that restricted these uses have seen reductions in antimicrobial resistance in human pathogens. This demonstrates that the relationship between animal use and human resistance is real and reversible. <extrainfo> Some countries have implemented complete bans on routine antimicrobial use in healthy animals, while others have implemented more gradual restrictions. The effectiveness varies by region based on enforcement and compliance. </extrainfo> Infection Prevention and Control Perhaps counterintuitively, preventing infections in the first place is one of the most powerful antimicrobial stewardship strategies. If infections don't occur, antibiotics don't need to be used—and no selective pressure for resistance is applied. In healthcare settings, basic infection-control practices include: Hand hygiene (the single most important intervention) Proper sterilization of instruments and equipment Appropriate use of personal protective equipment Isolation protocols for infectious patients In the community, infrastructure improvements are equally important: Access to clean water Proper sanitation and sewage disposal Safe food handling and storage Vaccination programs These measures reduce both the transmission of existing resistant organisms and the overall burden of infection that would otherwise require antibiotics. Research, New Drugs, and Alternatives Stewardship and infection prevention can slow resistance, but they cannot stop it entirely. Bacteria evolve continuously, and eventually resistant strains will emerge against even our most carefully used drugs. This reality makes investment in research and development essential: New antibiotics with novel mechanisms of action can treat resistant infections that older drugs cannot. However, the pipeline of new antibiotics is insufficient—fewer new antibiotics have been approved in recent decades compared to the 1980s and 1990s, even as resistance has accelerated. Alternative therapies such as bacteriophage therapy (using viruses that infect bacteria), probiotics, and immunotherapies are being developed to provide options beyond traditional antibiotics. Rapid diagnostic tests that quickly identify which bacteria is causing an infection and what antibiotics it's susceptible to enable faster, more targeted treatment and reduce inappropriate prescribing. Vaccines prevent infections before they start, reducing the need for antimicrobial treatment entirely. This is perhaps the most elegant prevention strategy. The challenge is that developing new antimicrobials is expensive, time-consuming, and increasingly unprofitable—since stewardship programs encourage their limited use once approved. This creates an economic paradox that requires government support and new funding models. <extrainfo> Some proposed solutions include: Extended patent protections or market exclusivity for novel antibiotics Direct government funding for antimicrobial development "Pull" mechanisms where governments guarantee purchase of new antibiotics Pricing models that reward innovation rather than volume of sales </extrainfo> Global Coordination and the One Health Approach Antimicrobial resistance doesn't respect borders. Resistant bacteria spread through travel, trade, and the movement of animals and food products. This global nature of the problem requires coordinated responses. The One Health approach integrates efforts across three interconnected sectors: Human health: Hospital and primary-care stewardship, appropriate antibiotic use, infection prevention Animal health: Reducing unnecessary antimicrobials in agriculture, treating diseased animals appropriately, improving animal welfare and housing Environmental stewardship: Reducing antimicrobial contamination in water supplies and soil, proper disposal of pharmaceutical waste, controlling contamination from manufacturing sites These three sectors are deeply interconnected. Resistant bacteria in animals can transfer to humans through the food chain. Antimicrobials excreted in human urine enter wastewater and can contaminate the environment. Polluted water sources spread bacteria back to both humans and animals. Coordination mechanisms that operationalize One Health include: National action plans developed by each country, with clear targets and timelines Cross-sectoral collaboration bringing together human health, agriculture, environmental, and regulatory agencies Surveillance systems that track resistance patterns across all three sectors Resource sharing and technical support between countries The diagram shows how resistance spreads across multiple pathways: from healthcare settings, from animal agriculture, through community transmission, and via environmental contamination. Effective prevention requires addressing all these pathways simultaneously. Global Action Plans and Commitments The WHO Global Action Plan (2015) The World Health Organization's Global Action Plan on Antimicrobial Resistance established five key objectives: Improve awareness and education about antimicrobial resistance among healthcare workers, policymakers, and the public Strengthen surveillance and research to track resistance patterns and understand transmission mechanisms Reduce infection incidence through vaccination, sanitation, and hygiene improvements Optimize antimicrobial use in both humans and animals by implementing stewardship programs and restricting growth promotion Develop sustainable investment for new medicines, diagnostics, and vaccines to stay ahead of emerging resistance The UN High-Level Meeting (2024) In 2024, world leaders at a United Nations High-Level Meeting made a specific commitment: to reduce the estimated 4.95 million human deaths associated with bacterial antimicrobial resistance by 10% by 2030. This represents formal acknowledgment that AMR is a global health priority requiring coordinated government action, not just clinical practice changes. <extrainfo> The UN commitment came despite economic pressures and competing global health priorities, reflecting growing recognition of AMR as a threat equal to or exceeding other major infectious diseases. </extrainfo> Summary: An Integrated Approach Prevention and control of antimicrobial resistance is not achieved by any single strategy but rather through integrated efforts at multiple levels: Individual patients complete prescribed courses and avoid unnecessary antibiotics Primary-care clinicians use decision-support tools and the five rights of prescribing Hospital systems employ stewardship teams and protocols Countries implement the WHO AWaRe classification and national action plans Agriculture sectors restrict growth-promotion antimicrobials Public health strengthens infection prevention and vaccination Researchers develop new drugs and alternatives Global institutions coordinate efforts across borders and sectors Each level reinforces the others. When hospitals reduce inappropriate use, they create selective pressure on bacteria to develop resistance more slowly, which extends the useful life of our current drugs while giving researchers more time to develop new ones. When vaccination prevents infections, fewer antibiotics are used overall, benefiting everyone. The challenge ahead is translating these strategies from plans on paper to consistent action in clinical practice and policy. This requires sustained commitment, adequate funding, and coordination among competing interests—but the evidence shows that it works.